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Low-frequency coding DNA sequence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-den-
sity lipoprotein cholesterol (LDL-C), protect against risk of coronary heart disease (CHD), and have prompted the development of a new
class of therapeutics. It is uncertain whether the PCSK9 example represents a paradigm or an isolated exception. We used the ‘‘Exome
Array’’ to genotype >200,000 low-frequency and rare coding sequence variants across the genome in 56,538 individuals (42,208 Euro-
pean ancestry [EA] and 14,330 African ancestry [AA]) and tested these variants for association with LDL-C, high-density lipoprotein
cholesterol (HDL-C), and triglycerides. Although we did not identify new genes associated with LDL-C, we did identify four low-fre-
quency (frequencies between 0.1% and 2%) variants (ANGPTL8 rs145464906 [c.361C>T; p.Gln121*], PAFAH1B2 rs186808413
[c.482C>T; p.Ser161Leu], COL18A1 rs114139997 [c.331G>A; p.Gly111Arg], and PCSK7 rs142953140 [c.1511G>A; p.Arg504His])
with large effects on HDL-C and/or triglycerides. None of these four variants was associated with risk for CHD, suggesting that examples
of low-frequency coding variants with robust effects on both lipids and CHD will be limited.Introduction
Recently, a compelling new therapeutic target for lowering
low-density lipoprotein cholesterol (LDL-C) emerged from
human genetics: the proprotein convertase subtilisin/
kexin type 9 gene (PCSK9 [MIM 607786]).1,2 PCSK9 pro-
tein-coding sequence variants that are low in frequency
(defined here as allele frequencies from 0.1% to 5%) have
been associated with lower plasma LDL-C3 and reduced
risk for coronary heart disease (CHD).4 With the identifica-
tion of low-frequency variants that protected against CHD,
many pharmaceutical companies have established drug
development programs targeting PCSK9. These observa-
tions have raised the question of whether the PCSK9
example is a paradigm for complex diseases like CHD or
an exception.5
Low-frequency DNA sequence variants and rare alleles
(defined here as <0.1% allele frequency) are poorly charac-
terized by earlier generations of genome-wide association
study (GWAS) genotyping arrays.6 Sequencing across the
exome or genome can directly assay low-frequency and
rare variants but such an approach is currently too costly
to study tens of thousands of individuals. One proposed
method for testing low-frequency and rare DNA variation
is to first sequence the exome to discover variation and,
subsequently, to genotype the discovered variants in a
larger number of individuals from the same or similar pop-
ulations to test for association with phenotype. Based on
this principle, the Illumina HumanExome genotyping
array (‘‘the Exome Array’’ or ‘‘Exome Chip’’) was designed
based on coding sequence variants discovered from
sequencing the exomes of ~12,000 individuals.
Here, we set out to address two questions: (1) are there
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if so, will these coding sequence variants also associate
with risk of clinical CHD? To address these questions,
we first genotyped and analyzed the Exome Array in
42,208 European ancestry (EA) individuals and 14,330
African ancestry (AA) individuals from 13 cohorts with
blood levels of fasting low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C),
and fasting triglycerides (TG). We subsequently tested
validated lipid variants for association with CHD. We
discovered four variants associated with HDL-C and/or
TG, but these variants did not associate with CHD.Subjects and Methods
Estimation of Proportion of Variation Captured by
Exome Array
We identified EA (n ¼ 3,173) and AA (n ¼ 2,408) participants
from the Atherosclerosis Risk in Communities (ARIC) Study with
available exome sequence who were not among the ~12,000
individuals utilized to design the Exome Array. Separately by
ancestry, we identified all variants with a minor allele frequency
(MAF) >0.1% from exome sequencing of these independent
ARIC individuals. These variants were compared with the variants
available on the Illumina HumanExome v.1.0 array.
Study Participants
Thirteen studies genotyped the Exome Array on a total of 56,538
participants (Table S1 available online). 42,208 individuals were
of European ancestry from ARIC, AGES, CHS, FHS, RS, MESA,
WHI, CARDIA, Health ABC, FamHS, LBC1936, and Korcula. A
total of 14,330 subjects were of African ancestry from ARIC,
CHS, MESA, Health ABC, FamHS, JHS, WHI, and CARDIA. All par-
ticipants provided informed consent and each study was approved
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Genotyping and Quality Control
All study participants were genotyped on the HumanExome Bead-
Chip v.1.0 (Illumina). ARIC, AGES, CHS, FHS, RS, MESA, CARDIA,
Health ABC, FamHS, and JHS were jointly called7,8 at the Univer-
sity of Texas Health Science Center at Houston. LBC1936 and Kor-
cula were called in GenomeStudio (Illumina) via the CHARGE
Consortium joint calling cluster file. WHI used zCalls.9 Variant
quality control (QC) was performed at the University of Texas
Health Science Center and by the individual cohorts. QC involved
checking concordance to GWAS data and excluding those individ-
uals missing >5% genotypes, population clustering outliers, indi-
viduals with high inbreeding coefficients or heterozygote rates,
individuals with gender mismatches, one individual from dupli-
cate pairs, and individuals with an unexpectedly high proportion
of identity-by-descent sharing, with consideration for family
studies, based on high-quality variants. All contributing studies
used an additive coding of variants to the minor allele observed
in the jointly called data set.Phenotypes
Association analyses were performed for three blood lipid traits in
mg/dl: LDL-C, HDL-C, and TG. Fasting lipids values were used
from the earliest available exam in each study. Studies with only
nonfasting lipid levels contributed only to the HDL-C analysis.
To account for lipid-lowering therapy in selected participants, we
sought to estimate the untreated lipid value in each participant.
Such an approach has been demonstrated to perform well in ac-
counting for treatment effects in studies of quantitative traits.10
Statins are the most widely used treatment to lower plasma lipids
and a statin at average dose reduces total cholesterol (TC) by 20%
and LDL-C by 30%.11 Statins became routinely used after the pub-
lication of the seminal 4S randomized control trial in 1994.12
If the sample was collected after 1994, we accounted for lipid-
lowering medication in the following manner: the treated
TC value was divided by 0.8. No adjustment was done on data
collected before 1994 unless specific information on statin use was
available. LDL-C was calculated via the Friedewald equation13,14
(LDL-C ¼ TC – HDL-C – (TG/5)) for those with TG <400 mg/dl. If
TG >400 mg/dl, calculated LDL-C was set to missing. If TC was
modified as described above for medication use, the modified total
cholesterol was used to calculate LDL-C. If only measured LDL-C
was available ina study,weaccounted for lipid-loweringmedication
in the following manner: the treated LDL-C value was divided by
0.7. No adjustments for medication use were made for HDL-C and
TG. TG was natural log transformed for analysis.Statistical Analyses
Single-variant, conditional, and gene-based analyses were con-
ducted with the seqMeta package in R. In brief, seqMeta imple-
ments efficient single-variant and gene-based meta-analysis.
Each study computes association-specific statistics for each variant
and trait assuming an additive model, and genotypic covariance
matrices within predefined gene regions. Score statistics and geno-
typic covariancematrices are combined across studies to obtain an
overall score statistic for each variant and a combined covariance
matrix across studies. The combined score statistic is used for the
single-variant results. For each gene, the score statistics for the var-
iants within the gene along with the combined covariance matrix
across those variants are used to construct the gene-based tests. An
additive effect of each variant is assumed for individuals carrying
more than one rare variant. All analyses were performed separatelyThe Americby race. We chose to meta-analyze EA and AA participants sepa-
rately to minimize population biases and to increase the number
of variants at specific MAF thresholds where there could be vastly
different frequencies in the two ancestries.
Single-Variant Analysis
Though we defined low-frequency variants as having a MAF
between 0.1% and 5%, we restricted single-variant tests to non-
synonymous and splice site variants with a MAF >0.02% in EA
individuals (nvariants ¼ 54,837) and >0.07% in AA individuals
(nvariants ¼ 90,218), corresponding to approximately 20 copies of
the minor allele in each ancestry sample. Twenty copies of the
minor allele provided stable estimates of the standard errors of
the beta estimates and well-calibrated quantile-quantile plots.
Gene-Based Analysis
We constructed gene-based tests from the cohort-combined
variant statistics and LD matrices. We only included nonsynony-
mous and splice site variants when producing the gene-based
statistics. We performed three gene-based tests: (1) T1, where all
variants with a MAF <1% were collapsed into gene-based
score;15 (2) T0.1, where all variants with a MAF <0.1% were
collapsed into gene-based score; and (3) sequence kernel associa-
tion test (SKAT)16 at a MAF <5%. SKAT is more powerful than
T1 when there are both protective and deleterious variants with
different magnitudes in the same gene whereas T1 and T0.1 are
more powerful when the magnitudes and directions of effect for
the individual variants in a gene are consistent. We filtered gene-
based results with a cumulative MAF<0.05% in the EA individuals
and <0.14% in the AA individuals for SKAT analyses, correspond-
ing to approximately 40 copies of the minor allele. For the T1 and
T0.1 tests, we used a cumulative MAF >0.04% for the EA individ-
uals and >0.11%, corresponding to 30 copies of the minor allele
across all cohorts. Simulations under the null (i.e., no associations)
were performed to determine the thresholds to control type I error
for the burden tests (results not shown). The gene-based T1 and
T0.1 analyses were limited to genes with at least two variants
contributing to the test. For EA, T1 analysis included 12,351 genes
with a cumulative MAF>0.04% and T0.1 with 8,357 genes; for AA
participants, T1 analysis included 13,574 genes with a cumulative
MAF >0.11% and T0.1 with 7,579 genes.
All analyses included age, age2, sex, and up to the first four prin-
cipal components of ancestry as covariates. Cohort statistics were
adjusted for related individuals, where appropriate. Beta coeffi-
cients were checked for consistency across the individual studies
contributing to the meta-analysis. Hardy-Weinberg equilibrium
p values were calculated and cluster plots from the joint calling
were verified for the reported associations (Figure S1). Fasting
glucose at baseline (between 1987 and 1989) in ARIC EA and
exam 5 (between 1991 and 1995) in FHS was tested for association
with rs145464906 in ANGPTL8 by linear regression adjusting for
age, sex, and PCs.
Population Structure
Each study identified components to correct for population struc-
ture in their study and used these components as covariates in all
association analyses.
Conditional Analysis
The allele dosages (0–2 copies) of the top previously identified
GWAS variants in each region were used as additional covariates
in the association model.
Statistical Significance
For single-variant association, we set the significance threshold
to <3 3 108, corresponding to a Bonferroni correction
for 1,485,864 tests (3 phenotypes 3 247,644 variants on thean Journal of Human Genetics 94, 223–232, February 6, 2014 225
array3 2 ancestries). For the gene-based association, we set the sig-
nificance threshold to <2 3 107, corresponding to a Bonferroni
correction for 316,332 tests (3 phenotypes 3 17,574 genes on the
array3 3 tests3 2 ancestries).
Annotation
We used dbNSFP v.2.0 to annotate the variants.17Clinical CHD Association Analysis
Individuals from AGES, ARIC, CHS, FHS, MESA, Health ABC, RS1,
WHI, MDC-CVA, IPM, ATVB/VHS, Ottawa, Procardis, Duke, and
Penn contributed to the CHD analysis in EA. Individuals from
ARIC, CHS, MESA, Health ABC, WHI, and IPM contributed to
the CHD analysis in AA. All individuals were genotyped on the
HumanExome BeadChip. Counts of number of CHD events in car-
riers and noncarriers of the four reported lipid variants were ob-
tained from each available study. A Cochran-Mantel-Haenszel
test was performed to associate the four reported lipid variants
with CHD by using the R metafor package across the contributing
studies.Power Calculation
Power for the CHD association was calculated via the case-control
for discrete traits option in the Genetic Power Calculator.Mouse Studies Involving PCSK7
We created an adeno-associated virus 8 (AAV8) vector encoding
the human PCSK7 coding region (cDNA) driven by the liver-spe-
cific thyroxine-binding globulin (TBG) promoter. An AAV8 vector
lacking any transgene was used as a control. Separate groups of
10- to 12-week-old wild-type C57BL/6J male mice (six to seven
per group) were injected via the peritoneal route with 13 1012 vec-
tor genomes/mouse of the relevant vectors. Mice were fed a regular
chow diet (Purina LabDiet 5010) throughout the study. Plasma
samples after 4 hr of fasting were taken from themice immediately
prior to vector administration, as well as 7 and 14 days after AAV
injection for analysis of lipids. Lipid measurements were per-
formed on a Roche Cobas-Mira autoanalyzer (Roche Diagnostic
Systems) with Wako Chemicals reagents. Mice were sacrificed at
14 days after AAV administration. All animal procedures were per-
formed according to the regulations of, and with the prior
approval of, the University of Pennsylvania Animal Care and
Use Committee (IACUC). We repeated this experiment in a sepa-
rate design comparing plasma lipids at baseline and 14 days after
injection of an AAV8 vector encoding the mouse Pcsk7 cDNA
versus control in wild-type C57BL/6J male mice (data not shown).Results
Coverage of Exome Array
We evaluated the coverage of Exome Array in samples in-
dependent from those used to design the array. Based on
exome sequences from 3,173 EA and 2,408 AA indepen-
dent participants, we estimate that the Illumina Exome
Array captures 78% of nonsynonymous coding and splice
site variation with >1:1,000 allele frequency in EA individ-
uals and 71% in AA individuals. Therefore, the array pro-
vides good coverage for low-frequency DNA variation
and because of its low cost can be assayed in a large num-
ber of individuals.226 The American Journal of Human Genetics 94, 223–232, FebruaryExome-sequencing variants not captured by the Exome
Array may have been dropped during the design of the
array. To address this possibility, we compared the variants
discovered from exome sequencing to proposed content of
the array (before variants failed design). We estimate that
95% of the variation in EA participants (and 85% of the
variation in AA) with frequency >1:1,000 is captured by
the proposed content of the array.Study Participants and Genotypes
Clinical characteristics of the 56,538 analyzed study sub-
jects are summarized in Table S1. Of the 247,644 variants
that passed quality control criteria, 85% (n ¼ 209,756)
are polymorphic in the EA participants and 82% (n ¼
202,255) are polymorphic in the AA participants. Approx-
imately 90% (n¼ 188,480) of the polymorphic variants are
annotated17 as nonsynonymous (nonsense or missense)
or splice variants in the EA participants, and 89% (n ¼
180,908) of the polymorphic variants are annotated as
such in the AA participants (Table 1).Single-Variant Association
We tested each variant individually for association with
blood lipid levels separately in each cohort and association
summary statistics across cohorts were combined by fixed
effects meta-analysis, separately within each ancestry
group. There was no evidence of inflation in the associa-
tion test statistics (Figure S2).
We replicated previously reported associations with
common and low-frequency variants (Table 2) in both EA
and AA participants. For example, we found that variants
in PCSK9 (c.137G>T [p.Arg46Leu], [rs11591147] in EA
and c.2037C>A [p.Cys679*], [rs28362286] in AA) were
associated with lower LDL-C (17 mg/dl; p ¼ 3 3 1059
and 40 mg/dl; p ¼ 2 3 1057, respectively).
We discovered four associations of low-frequency vari-
ants with either HDL-C and/or TG that met our a priori
significance threshold of p < 3 3 108 and not previously
reported in the literature. Two signals emerged from EA
participants and two from AA participants (Table 3). In
contrast to HDL-C and TG, we did not discover any new
genes where low-frequency or rare DNA sequence variants
significantly associated with LDL-C. Below, we describe
each of the four new associations.
First, in EA participants, we found an association
of blood HDL-C with a 0.1% premature stop codon
at the chromosome 19 open reading frame 80 gene
(C19orf80, aliases include ANGPTL8, lipasin, and betatro-
phin; c.361C>T [p.Gln121*]; rs145464906). Carriers of
ANGPTL8 rs145464906 had 10 mg/dl higher HDL-C (p ¼
5 3 1011), lower TG (15%; p ¼ 0.003), and nonsignifi-
cantly lower LDL-C (5.8 mg/dl; p ¼ 0.13) than did non-
carriers of this variant (Table 4). ANGPTL8 rs145464906
is seen at a 0.01% frequency in AA participants and
we were not able to reliably estimate its effect on lipid
measures in this group.6, 2014
Table 1. Number of Exome Array Variants Available for Analysis by Variant Type
Variant Type All Polymorphic Sites MAF < 0.1% MAF 0.1%–5% MAF > 5%
42,208 European Ancestry Samples
Nonsynonymous 175,444 130,553 32,501 12,390
Nonsense/splice 13,036 10,694 1,686 656
Synonymous 5,444 3,710 978 756
Intronic/Intergenic 14,205 139 1,186 12,880
Other 1,627 156 199 1,272
14,330 African Ancestry Samples
Nonsynonymous 169,140 91,083 61,809 16,248
Nonsense/splice 11,768 7,729 3,177 862
Synonymous 5,398 2,341 2,098 959
Intronic/Intergenic 14,169 56 650 13,463
Other 1,780 116 356 1,308
Variant type was determined based on dbNSFP v.2.0 annotations. Abbreviation is as follows: MAF, minor allele frequency. Other category includes variants labeled
as downstream (n¼ 187), ncRNA_exonic (n¼ 111), ncRNA_intronic (n¼ 447), ncRNA_splicing (n¼ 1), ncRNA_UTR3 (n¼ 8), _UTR5 (n¼ 1), upstream (n¼ 181),
upstream;downstream (n ¼ 8), UTR3 (n ¼ 518), UTR5 (n ¼ 77).ANGPTL8 rs145464906 is located in a genomic
region previously associated with lipid levels in
GWASs (rs737337 at the DOCK6 [MIM 614194] locus;
c.2136A>G [p.(¼)]).18 An analysis conditioning on
rs737337 in DOCK6 revealed rs145464906 to be an inde-
pendent association (pconditional ¼ 5.5 3 1013). Another
more common coding variant in ANGPTL8 (8% frequency;
rs2278426; c.175C>T [p.Arg59Trp]) has been associated
with low LDL-C and low HDL-C.19 This variant is not
present on the exome array, but the correlation between
rs2278426 and rs145464906 is low at 0.08 and conditional
analyses confirm that rs2278426 and rs145464906 are
independent association signals (data not shown).
Angplt8-null mice display lower blood TG and func-
tional studies have suggested that ANGPTL8 may activate
ANGPTL3 and thereby regulate lipoprotein meta-
bolism.19,20 Of note, based on studies inmice, another pro-
posed role for ANGPTL8 is as a hormone that promotes
pancreatic b cell proliferation, expands b cell mass, and
improves glucose tolerance.21 These studies raise the hy-
pothesis that loss of ANGPTL8 functionmightworsenmea-
sures of glucose tolerance. We studied the association of
ANGPTL8 rs145464906 with fasting plasma glucose levels
among 10,642 EA participants in the ARIC study and
3,112 EA participants from FHS and observed no evidence
for association in either study. In ARIC, plasma glucose
did not differ between the carriers of the rs145464906 allele
(n ¼ 23) and noncarriers (n ¼ 10,620) (beta ¼ 3.3 mg/dl;
SE ¼ 5.8 mg/dl; p ¼ 0.57). In FHS, carriers of rs145464906
(n ¼ 13) had a mean fasting glucose of 88.2 mg/dl whereas
noncarriers had mean glucose of 99.9 mg/dl (p ¼ 0.13).
A second discovery among EA participants is a signifi-
cant association between a 1% frequency variant in the
Platelet-Activating Factor Acetylhydrolase 1b, CatalyticThe AmericSubunit 2 gene (PAFAH1B2 [MIM 602508]; c.482C>T
[p.Ser161Leu]; rs186808413) and HDL-C. Carriers of
rs186808413 had 3 mg/dl higher HDL-C (p ¼ 2.2 3
1010), lower TG (10%; p ¼ 2.3 3 109), and marginally
lower LDL-C (3 mg/dl; p ¼ 0.01) than did noncarriers
(Table 4). In AA participants, the direction of association
between HDL-C and PAFAH1B2 rs186808413 (0.2% fre-
quency in AA participants) was consistent with the EA
results, but not significant (1 mg/dl; p ¼ 0.58). PAFAH1B2
is located near the chromosome 11 gene cluster involving
APOA1/C3/A4/A5, a region where several genes regulate
TG. Conditional analysis adjusting for six previously
studied variants in this region (rs964184, rs3135506,
rs2266788, rs76353203, rs147210663, rs140621530)
showed PAFAH1B2 rs186808413 to be an independent
association signal (pconditional ¼ 2.1 3 1011). Platelet-
activating factor (PAF) is a lipid messenger functioning
in many cellular processes.22 Plasma platelet-activating
factor-acetyl hydrolase (PAF-AH) belongs to a subfamily
of phospholipases A2 that remove the sn-2 acetyl group
and inactivate a number of oxidized lipids,23,24 but intra-
cellular type I (PAF-AH-Ib) is structurally distinct and
may form a part of a signal transduction pathway.22
Third, among AA participants, we found an association
of blood TG with a 2% frequency variant in the Collagen,
Type XVIII, Alpha 1 gene (COL18A1 [MIM 120328];
c.331G>A [p.Gly111Arg]; rs114139997), where carriers of
rs114139997 had 16% lower TG than did noncarriers
(p ¼ 2 3 1016). COL18A1 rs114139997 was also margin-
ally associated with higher HDL-C (2 mg/dl; p ¼ 4 3
104) (Table 4). The frequency of COL18A1 rs114139997
is 0.003% in EA participants and we were not able to reli-
ably estimate the effect on lipid measures in this group.
COL18A1 is a basement membrane proteoglycan with aan Journal of Human Genetics 94, 223–232, February 6, 2014 227
Table 2. Top Association Results for Low-Frequency Variants Based on Level of Statistical Significance
Gene dbSNP ID Mutation (Substitution) Chr: Positiona MAFb Betac p Value
HDL-C – EA (n ¼ 42,208)
ANGPTL4 rs116843064 c.118G>A (p.Glu40Lys) 19: 8,429,323 2.01% 4 mg/dl 1.7 3 1029
LIPG rs77960347 c.1187A>G (p.Asn396Ser) 18: 47,109,955 1.27% 5 mg/dl 5.1 3 1027
LPL rs268 c.953A>G (p.Asn318Ser) 8: 19,813,529 1.78% 3 mg/dl 2.4 3 1019
LDL-C – EA (n ¼ 39,186)
PCSK9 rs11591147 c.137G>T (p.Arg46Leu) 1: 55,505,647 1.54% 17 mg/dl 2.7 3 1059
APOB rs5742904 c.10580G>A (p.Arg3527Gln) 2: 21,229,160 0.05% 71 mg/dl 5.6 3 1034
CBLC rs3208856 c.1075C>T (p.His359Tyr) 19: 45,296,806 3.43% 8 mg/dl 6.2 3 1030
Triglycerides – EA (n ¼ 39,859)
ANGPTL4 rs116843064 c.118G>A (p.Glu40Lys) 19: 8,429,323 2.02% 15% 2.9 3 1037
LPL rs268 c.953A>G (p.Asn318Ser) 8: 19,813,529 1.76% 14% 1.2 3 1022
MAP1A rs55707100 c.7046C>T (p.Pro2349Leu) 15: 43,820,717 3.25% 9% 1.4 3 1017
HDL-C – AA (n ¼ 14,330)
PCSK7 rs142953140 c.1511G>A (p.Arg504His) 11: 117,089,205 0.2% 17 mg/dl 3.4 3 1020
CETP rs34119551 c.17T>A (p.Val6Asp) 16: 56,995,908 0.24% 16 mg/dl 2.0 3 1019
LCAT rs35673026 c.340G>A (p.Val114Met) 16: 67,976,851 0.34% 10 mg/dl 2.0 3 1010
LDL-C – AA (n ¼ 14,227)
PCSK9 rs28362286 c.2037C>A (p.Cys679*) 1: 55,529,215 0.87% 40 mg/dl 1.5 3 1057
PCSK9 rs67608943 c.426C>G (p.Tyr142*) 1: 55,512,222 0.30% 35 mg/dl 2.6 3 1016
APOE rs769455 c.487C>T (p.Arg163Cys) 19: 45,412,040 1.93% 12 mg/dl 3.6 3 1012
Triglycerides – AA (n ¼ 14,351)
APOE rs769455 c.487C>T (p.Arg163Cys) 19: 45,412,040 1.93% 21% 2.3 3 1018
COL18A1 rs114139997 c.331G>A (p.Gly111Arg) 21: 46,875,775 1.93% 16% 1.6 3 1011
ZNF259 rs35120633 c.791C>T (p.Ala264Val) 11: 116,655,600 2.96% 13% 2.7 3 1012
Results are based on 42,208 European ancestry (EA) individuals and 14,330 African ancestry (AA) individuals.
aChr: Position is reported in UCSC Genome Browser build hg19.
bMAF, minor allele frequency.
cBeta is based on the geometric mean for triglycerides.recently established role in presenting the enzyme lipo-
protein lipase to the luminal side of the vascular endothe-
lium.25 Mice deleted for Col18a1 (Col18a1/) were shown
to have hypertriglyceridemia resulting from decreased
lipoprotein lipase activity, and humans with homozy-
gous deficiency of COL18A1 (Knobloch syndrome [MIM
267750]) have been observed to have higher blood TG
than do normal individuals.25
Finally, in AA participants, we also identified an associa-
tion of blood HDL-C with a 0.2% frequency variant at the
proprotein convertase subtilisin/kexin type 7 serine prote-
ase gene (PCSK7 [MIM 604874]; c.1511G>A [p.Arg504His];
rs142953140). Carriers of the PCSK7 rs142953140 muta-
tion had 17 mg/dl higher HDL-C levels than did non-
carriers (p ¼ 5 3 1020). PCSK7 rs142953140 was also
associated with lower TG (30%; p ¼ 2 3 109) and nomi-
nally associated with lower LDL-C (11.5 mg/dl; p ¼ 0.02)
among the AA participants (Table 4). PCSK7 is located228 The American Journal of Human Genetics 94, 223–232, Februarynear the chromosome 11 gene cluster involving APOA1/
C3/A4/A5, a region where several genes regulate HDL-C
and TG. Conditional analysis adjusting for six known
variants in this region (rs964184, rs3135506, rs2266788,
rs76353203, rs147210663, rs140621530) showed PCSK7
rs142953140 to be an independent association signal
(pconditional ¼ 3.4 3 1020). PCSK7 rs142953140 was not
polymorphic in individuals of European ancestry. PCSK7
belongs to the same family of serine proteases as does
PCSK9, and a putative link between PCSK7 and lipoprotein
metabolism was recently established in vitro.26,27 In
cultured cells, PCSK7 cleaved angiopoietin-like protein 4
(ANGPTL4) and activated its ability to inhibit lipoprotein
lipase.
We studied the functional consequence of overexpres-
sion of human PCSK7 in mice and found that mice over-
expressing PCSK7 in liver have lower HDL-C and higher
TG compared to controls (Figure 1), suggesting that gain6, 2014
Table 3. Variant Associations with Blood Lipids that Have Not Been Previously Reported
Trait Gene rsID Mutation (Substitution) Betaa p Value Conditional Variants pconditional EA MAF AA MAF
Ancestry: EA
HDL-C ANGPTL8 rs145464906 c.361C>T (p.Gln121*) 10 mg/dl 5.1 3 1011 rs737337 5.5 3 1013 0.1% 0.01%
HDL-C PAFAH1B2 rs186808413 c.482C>T (p.Ser161Leu) 3 mg/dl 2.2 3 1010 rs964184, rs3135506,
rs2266788, rs76353203,
rs14721066, rs140621530
2.1 3 1011 1.1% 0.2%
Ancestry: AA
TG COL18A1 rs114139997 c.331G>A (p.Gly111Arg) 16% 1.6 3 1016 – – 0.003% 1.9%
HDL-C PCSK7 rs142953140 c.1511G>A (p.Arg504His) 17 mg/dl 4.9 3 1020 rs964184, rs3135506,
rs2266788, rs76353203,
rs14721066, rs140621530
3.4 3 1020 0% 0.2%
Results are based on 42,208 European ancestry (EA) individuals and 14,330 African ancestry (AA) individuals. Abbreviations are as follows: TG, triglycerides;
HDL-C, high-density lipoprotein cholesterol; MAF, minor allele frequency.
aEffect estimate for triglycerides is based on the geometric mean.of PCSK7 function decreases HDL-C and increases TG
in vivo. Further studies are warranted to determine
whether reduction of hepatic PCSK7, for example through
Pcsk7 knockdown in mice, will result in the same lipid
profile as that of human subjects with the PCSK7
rs142953140 mutation.
Gene-Based Association
In contrast to low-frequency variants, the alternative al-
leles at rare variants occur too infrequently to be analyzed
individually and must be evaluated by aggregating into
sets. Here, typically, the unit of analysis is a gene. We
used two methods to perform gene-based analyses incor-
porating variants annotated as nonsynonymous or splice
site: the sum of the number of minor alleles15 including
variants with a MAF <1% or MAF <0.1% and the sequence
kernel association test (SKAT),16 a test that considers effectTable 4. Association Results in Other Lipid Traits for the Reported As
Gene rsID Trait EA Beta
ANGPTL8 rs145464906 HDL-C 10 mg/dl
TG 15%
LDL-C 5.8 mg/dl
PAFAH1B2 rs186808413 HDL-C 3 mg/dl
TG 10%
LDL-C 3 mg/dl
COL18A1 rs114139997 HDL-C –
TG –
LDL-C –
PCSK7 rs142953140 HDL-C –
TG –
LDL-C –
Abbreviations are as follows: TG, triglycerides; HDL-C, high-density lipoprotein cho
African ancestry; Beta, effect size.
The Americsizes in both directions, including variants with a MAF
<5%. Gene-based association results were well calibrated
(Figure S3). We were able to replicate genes previously
reported to be associated with blood lipid levels (Table 5).
For example, multiple rare alleles at LDLR (MIM 606945)
were strongly associated with blood LDL-C (p ¼ 5 3
1010). No new genetic associations were identified
through the gene-based analyses.
Association with CHD
To assess whether the four newly associated low-frequency
coding variants also relate to clinical cardiovascular dis-
ease, we tested association of each variant with CHD
in 63,470 individuals from 15 EA studies and 13,772
individuals from 7 AA studies (Table S2). Of these partici-
pants, 14,201 EA and 2,380 AA individuals were affected
with CHD.sociations
EA p Value AA Beta AA p Value
5.1 3 1011 – –
0.003 – –
0.13 – –
2.2 3 1010 1 mg/dl 0.58
2.3 3 1009 4% 0.48
0.01 2.6 md/dl 0.58
– 2.2 mg/dl 4.1 3 104
– 16% 1.6 3 1016
– 2.6 mg/dl 0.12
– 17 mg/dl 4.9 3 1020
– 30% 1.5 3 1009
– 11.5 mg/dl 0.02
lesterol; LDL-C, low-density lipoprotein cholesterol; EA, European ancestry; AA,
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Figure 1. Effects of Human PCSK7 Overexpression in Mouse
Liver on Plasma Lipids
Plasma TC (A), HDL-C (B), and TG (C) were measured at baseline
and at 7 and 14 days after injection of the human PCSK7 or control
AAV8 vectors in C57BL/6J male mice. Error bars show standard
deviations. *p < 0.05 and **p < 0.01, Student’s unpaired t test.
Table 5. Top Gene-Based Association Results Based on Level of
Statistical Significance
Gene p Value
Best
Test Betaa SE CMAFb
No.
Variantsc
LDL-EA
PCSK9 1.81 3 1062 SKAT – – 0.0626 22
LDLR 4.9 3 1010 T1 15.36 2.47 0.0027 28
HDL-EA
APOC3 3.2 3 1019 T1 11.75 1.31 0.0035 4
ANGPTL4 5.41 3 1030 SKAT – – 0.0283 11
LIPG 2.55 3 1029 SKAT – – 0.0162 12
LPL 5.76 3 1029 SKAT – – 0.0372 10
Triglycerides-EA
APOC3 4.0 3 1029 T1 0.41 0.05 0.0036 4
ANGPTL4 2.70 3 1037 SKAT – – 0.0286 11
LPL 1.56 3 1031 SKAT – – 0.037 10
LDL-AA
PCSK9 1.40 3 1071 SKAT – – 0.1295 25
APOE 2.65 3 1012 SKAT – – 0.0205 3
HDL-AA
APOC3 9.5 3 1012 T1 10.14 1.49 0.0055 4
CETP 7.7 3 1009 T1 6.18 1.07 0.0065 7
Triglycerides-AA
APOC3 2.9 3 1019 T1 0.34 0.05 0.0055 4
APOE 2.26 3 1018 SKAT – – 0.0205 3
Abbreviations are as follows: TG, triglycerides; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; EA, European ancestry;
AA, African ancestry; Beta, effect size; SE, standard error.
aBeta is in mg/dl units for LDL and HDL and in percent change for triglycerides.
bCMAF, cumulative minor allele frequency of the variants contributing to
the test.
cNo. variants, number of variants contributing to the test.As a positive control, we confirmed that the PCSK9
c.137T (c.137G>T [p.Arg46Leu]; rs11591147) allele lead-
ing to lower LDL-C was associated with reduced risk for
CHD among EA participants (OR ¼ 0.84, 95% CI ¼ 0.74–
0.95, p ¼ 0.007) and PCSK9 c.2037A (c.2037C>A
[p.Cys679*]; rs28362286) allele leading to lower LDL-C
was similarly associated with reduced risk for CHD
among AA participants (OR ¼ 0.40, 95% CI ¼ 0.23–0.68,
p ¼ 5.4 3 104).
In contrast to the PCSK9 variants, none of the four cod-
ing sequence variants at ANGPTL8, PAFAH1B2, COL18A1,
or PCSK7 were associated with risk for CHD (Table 6).Discussion
The contribution of low-frequency DNA sequence varia-
tion to complex phenotypes such as blood lipids and230 The American Journal of Human Genetics 94, 223–232, FebruaryCHD has been the subject of much debate. Some have
argued that low-frequency variants with large effects may
be instrumental in discovering genes and that such discov-
eries can lead to novel therapeutic targets. By using the
Exome Array in >42,000 EA individuals and >14,000 AA
individuals, we discovered four low-frequency variants
with large effects on lipids, but none of these variants asso-
ciated with risk for CHD.
Several limitations of our study deserve mention. We
were not able to evaluate extremely rare variants that
may be unique to individuals; exome or whole-genome
sequencing is needed to capture this type of variation. As
such, it remains possible that a burden of such very rare
mutations could contribute to plasma lipid variation. If
so, the sample sizes required to yield new rare variant
discoveries are likely to be extraordinarily large.
The Exome Array is constrained to the coding and splice
site variation observed in the ~12,000 individuals who
comprised the initial exome sequencing discovery set.6, 2014
Table 6. Association of Lipid Variants with Coronary Heart Disease
Gene Mutation (Substitution) rsID Case Frequency Control Frequency Odds Ratio p Value
Ancestry: EA
ANGPTL8 c.361C>T (p.Gln121*l) rs145464906 0.29% 0.27% 1.023 0.985
PAFAH1B2 c.482C>T (p.Ser161Leu) rs186808413 2.05% 2.23% 0.905 0.170
Ancestry: AA
PCSK7 c.1511G>A (p.Arg504His) rs142953140 0.53% 0.47% 1.258 0.592
COL18A1 c.331G>A (p.Gly111Arg) rs114139997 3.39% 3.38% 0.996 0.971
Association with CHD was performed in a total of 63,470 EA individuals and 13,772 AA individuals. 14,201 EA and 2,380 AA individuals developed CHD.Furthermore, ~20% of the content contributed for design
failed to be converted into genotyping assays and thus
these variants are not present on the Exome Array.
The lack of significant association of our reported low-
frequency variants with CHD may be due to insufficient
statistical power. For the CHD association testing among
EA participants, we had >80% power at a ¼ 0.05 to detect
an odds ratio outside the range (0.86, 1.14) with a 2% fre-
quency variant, and an odds ratio outside the range (0.74,
1.29) with a 0.5% frequency variant. Among AA partici-
pants, we had >80% power at a ¼ 0.05 to detect an odds
ratio outside the range (0.69, 1.35) with a 2% frequency
variant, and an odds ratio outside the range (0.43, 1.73)
with a 0.5% frequency variant.
Of note, all four of our reported loci were associated with
HDL-C, which may not be a causal risk factor for clinical
CHD, and this observation could explain the lack of asso-
ciation with CHD.28 Finally, we do not yet fully under-
stand the biologicmechanism bywhich the genes reported
here affect blood lipoproteins.
In summary, by using the ExomeArray,we identified four
low-frequency coding variants in ANGPTL8, PAFAH1B2,
COL18A1, and PCSK7 that altered plasma HDL-C and/or
TG but did not affect risk for CHD. These results suggest
that the example of PCSK9 with low-frequency alleles that
affect both plasma lipids and CHD is likely to be an excep-
tion rather than a paradigm.Supplemental Data
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